- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02628574
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors
This study will be conducted in 5 parts (Parts A, B, C, D and E).
Monotherapy Treatment:
Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A. Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part B).
Combination Treatment:
Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Subjects will receive TRX518 in combination with gemcitabine (Part C), pembrolizumab (Part D), or nivolumab (Part E). Dose escalation will be performed for each part (Part Cesc, Part Desc, Part Eesc) and Cycle 1 data from each cohort will be evaluated for safety and dose-limiting toxicities (DLTs) prior to dose escalation. Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a patient is enrolled and cohorts will be dosed consecutively by ascending dose. Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified, an expanded cohort will be enrolled (Part Cexp, Part Dexp, Part Eexp).
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- University of Chicago
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87131
- University of New Mexico Comprehensive Cancer Center
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic
-
Cleveland, Ohio, États-Unis, 44106
- University Hospitals
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37205
- Tennessee Oncology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Advanced Solid Malignancies: Histologically documented metastatic or locally advanced, incurable solid malignancy (Parts A and B); histologically documented metastatic or locally advanced, incurable solid malignancy for which gemcitabine is clinically appropriate (e.g., non-small cell lung, breast, ovarian, pancreatic, and renal cancer); histologically documented metastatic or locally advanced, incurable solid malignancy for which pembrolizumab (Part D) or nivolumab (Part E) is approved. NOTE: Parts D and E only: Subject has either (1) received treatment with pembrolizumab or nivolumab for ≥4 months with a best response of stable disease and plans to continue treatment with either pembrolizumab or nivolumab in accordance with package insert; or (2) is not currently taking, but is eligible for treatment with, pembrolizumab or nivolumab in accordance with the approved indications for each as referenced in the package insert.
- Expected survival of at least 12 weeks after dosing.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Evidence of adequate organ function by standard laboratory tests.
- All female subjects of child bearing age must be either surgically sterile, postmenopausal for at least 1 year, or using an acceptable method of contraception. Adequate contraception for both male and female subjects must be used from the beginning of the screening period until at least 8 weeks after the last dose of study drug.
Exclusion Criteria:
- Hematologic malignancies or multiple myeloma.
- Known, clinically important cardiac or respiratory disease
- Any concomitant serious physical illness other than cancer (e.g., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing. No history of autoimmune disease.
- Active, uncontrolled infections within 7 days of study entry requiring systemic therapy.
- Evidence of progression of central nervous system (CNS) metastases or symptomatic CNS metastases within 30 days prior to dosing.
- History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment. (Parts C, D and E only).
- Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis (Parts D and E only).
- Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment (Parts D and E only).
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis (Parts D and E only).
- History of interstitial lung disease (Parts D and E only).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: TRX518 monotherapy (Parts A and B)
Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
|
comparison of different (ascending) doses of TRX518 monotherapy
|
Expérimental: TRX518 with gemcitabine (Part C)
Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
|
comparison of different (ascending) doses of TRX518 in combination with gemcitabine
|
Expérimental: TRX518 with pembrolizumab (Part D
Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
|
comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
|
Expérimental: TRX518 with nivolumab (Part E)
Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
|
comparison of different (ascending) doses of TRX518 in combination with nivolumab
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Adverse events
Délai: through 30 days post last dose
|
Any adverse change in health or side effect from the initiation of the study drug dose TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab through completion or premature withdrawal
|
through 30 days post last dose
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
TRX518 peak concentration (Cmax)
Délai: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
Time to peak concentration (Tmax)
Délai: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
Area under the curve (AUC)
Délai: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
RECIST assessment for evidence of antitumor activity
Délai: up to 1 year
|
RECIST assessment to determine effects of TRX518 monotherapy and TRX518 in combination with gemcitabine, pembrolizumab or nivolumab on solid tumors.
|
up to 1 year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Cyndi Sirard, MD, Leap Therapeutics, Inc.
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents antiviraux
- Inhibiteurs d'enzymes
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents antinéoplasiques immunologiques
- Inhibiteurs de point de contrôle immunitaire
- Gemcitabine
- Nivolumab
- Pembrolizumab
Autres numéros d'identification d'étude
- TRX518-003
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeurs solides
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
-
Shattuck Labs, Inc.Actif, ne recrute pasMélanome | Carcinome à cellules rénales | Lymphome de Hodgkin | Adénocarcinome gastrique | Cancer du poumon non à petites cellules | Carcinome épidermoïde de la tête et du cou | Lymphome diffus à grandes cellules B | Carcinome urothélial | Adénocarcinome de la jonction gastro-oesophagienne | Carcinome... et d'autres conditionsÉtats-Unis, Canada, Belgique, Espagne
Essais cliniques sur TRX518 monotherapy
-
Leap Therapeutics, Inc.Cancer Research Institute, New York CityComplétéMélanome malin de stade III ou IV non résécable ou autres tumeurs malignes solidesÉtats-Unis
-
Leap Therapeutics, Inc.Pfizer; Merck KGaA, Darmstadt, GermanyRésiliéTumeurs solides | Cancer du sein triple négatif avancé | Cancer du sein avancé avec récepteurs hormonaux positifs/réfractaire endocrinien | Cancer de la prostate métastatique avancé résistant à la castration | Cancer de l'ovaire avancé résistant au platineÉtats-Unis